P63015.1
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
31,769 Da
NCBI Official Full Name
Paired box protein Pax-6
NCBI Official Synonym Full Names
paired box 6
NCBI Official Synonym Symbols
Dey; Sey; AEY11; Pax-6; Gsfaey11; 1500038E17Rik [Similar Products]
NCBI Protein Information
paired box protein Pax-6
UniProt Protein Name
Paired box protein Pax-6
UniProt Synonym Protein Names
Oculorhombin
UniProt Synonym Gene Names
UniProt Entry Name
PAX6_MOUSE
NCBI Summary for Pax6
This gene encodes a homeobox-containing protein that functions as a regulator of transcription. It plays a key role in the development of neural tissues, particularly the eye. Activity of this protein is also required for expression of glucagon in the pancreas. This gene is regulated by multiple enhancers located up to tens or hundreds of kilobases upstream and downstream of the transcription start sites. Mutations in this gene or deletion of these regulatory elements results in severe defects in eye development. Alternative splicing and the use of alternative promoters results in multiple transcript variants, some of which encode proteins that lack the N-terminal paired domain. [provided by RefSeq, Jul 2015]
UniProt Comments for Pax6
PAX6: Transcription factor with important functions in the development of the eye, nose, central nervous system and pancreas. Required for the differentiation of pancreatic islet alpha cells. Competes with PAX4 in binding to a common element in the glucagon, insulin and somatostatin promoters. Regulates specification of the ventral neuron subtypes by establishing the correct progenitor domains. Isoform 5a appears to function as a molecular switch that specifies target genes. Defects in PAX6 are the cause of aniridia (AN). A congenital, bilateral, panocular disorder characterized by complete absence of the iris or extreme iris hypoplasia. Aniridia is not just an isolated defect in iris development but it is associated with macular and optic nerve hypoplasia, cataract, corneal changes, nystagmus. Visual acuity is generally low but is unrelated to the degree of iris hypoplasia. Glaucoma is a secondary problem causing additional visual loss over time. Defects in PAX6 are a cause of Peters anomaly (PAN). Peters anomaly consists of a central corneal leukoma, absence of the posterior corneal stroma and Descemet membrane, and a variable degree of iris and lenticular attachments to the central aspect of the posterior cornea. Defects in PAX6 are a cause of foveal hypoplasia (FOVHYP). Foveal hypoplasia can be isolated or associated with presenile cataract. Inheritance is autosomal dominant. Defects in PAX6 are a cause of keratitis hereditary (KERH). An ocular disorder characterized by corneal opacification, recurrent stromal keratitis and vascularization. Defects in PAX6 are a cause of coloboma of iris choroid and retina (COI); also known as uveoretinal coloboma. Ocular colobomas are a set of malformations resulting from abnormal morphogenesis of the optic cup and stalk, and the fusion of the fetal fissure (optic fissure). Severe colobomatous malformations may cause as much as 10% of the childhood blindness. The clinical presentation of ocular coloboma is variable. Some individuals may present with minimal defects in the anterior iris leaf without other ocular defects. More complex malformations create a combination of iris, uveoretinal and/or optic nerve defects without or with microphthalmia or even anophthalmia. Defects in PAX6 are a cause of coloboma of optic nerve (COLON). Defects in PAX6 are a cause of bilateral optic nerve hypoplasia (BONH); also known as bilateral optic nerve aplasia. A congenital anomaly in which the optic disc appears abnormally small. It may be an isolated finding or part of a spectrum of anatomic and functional abnormalities that includes partial or complete agenesis of the septum pellucidum, other midline brain defects, cerebral anomalies, pituitary dysfunction, and structural abnormalities of the pituitary. Defects in PAX6 are a cause of aniridia cerebellar ataxia and mental deficiency (ACAMD); also known as Gillespie syndrome. A rare condition consisting of partial rudimentary iris, cerebellar impairment of the ability to perform coordinated voluntary movements, and mental retardation. Belongs to the paired homeobox family. 3 isoforms of the human protein are produced by alternative splicing.
Protein type: DNA-binding; Transcription factor; Motility/polarity/chemotaxis
Cellular Component: cytoplasm; intracellular; nuclear chromatin; nucleoplasm; nucleus; transcription factor complex
Molecular Function: AT DNA binding; chromatin binding; DNA binding; double-stranded DNA binding; histone acetyltransferase binding; protein binding; protein kinase binding; sequence-specific DNA binding; transcription factor activity; transcription factor binding; ubiquitin protein ligase binding
Biological Process: anterior/posterior pattern formation; astrocyte differentiation; axon guidance; axonogenesis; blood vessel development; brain development; camera-type eye development; cell differentiation; cell fate commitment; cell fate determination; cerebral cortex regionalization; commitment of a neuronal cell to a specific type of neuron in the forebrain; dorsal/ventral axis specification; dorsal/ventral pattern formation; embryonic camera-type eye morphogenesis; epithelial cell development; establishment of mitotic spindle orientation; eye photoreceptor cell development; forebrain development; forebrain dorsal/ventral pattern formation; forebrain-midbrain boundary formation; glucose homeostasis; habenula development; hindbrain development; interkinetic nuclear migration; keratinocyte differentiation; lacrimal gland development; lens development in camera-type eye; negative regulation of cell proliferation; negative regulation of epithelial cell proliferation; negative regulation of neuron differentiation; negative regulation of protein amino acid phosphorylation; neural crest cell migration; neuron migration; olfactory bulb development; oligodendrocyte cell fate specification; pallium development; pituitary gland development; positive regulation of cell fate specification; positive regulation of epithelial cell differentiation; positive regulation of neuroblast proliferation; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription, DNA-dependent; protein localization in organelle; regionalization; regulation of asymmetric cell division; regulation of cell migration; regulation of gene expression; regulation of neurogenesis; regulation of neuron differentiation; regulation of timing of cell differentiation; regulation of transcription from RNA polymerase II promoter; regulation of transcription from RNA polymerase II promoter involved in somatic motor neuron fate commitment; regulation of transcription from RNA polymerase II promoter involved in spinal cord motor neuron fate specification; regulation of transcription from RNA polymerase II promoter involved in ventral spinal cord interneuron specification; regulation of transcription, DNA-dependent; retina development in camera-type eye; rhombomere morphogenesis; salivary gland morphogenesis; smoothened signaling pathway; telencephalon regionalization; transcription from RNA polymerase II promoter
Research Articles on Pax6
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with Pax6 blocking peptide
Pathways associated with Pax6 blocking peptide
Diseases associated with Pax6 blocking peptide
Organs/Tissues associated with Pax6 blocking peptide
|